A JQ1 prodrug nanoparticle capable of cooperating with chemotherapy to reverse the tumor microenvironment, and its preparation method and application

By enriching and releasing JQ1 nanoparticles at the tumor, the problems of low delivery efficiency and immune escape of traditional chemotherapy drugs are solved, and the synergistic treatment of chemotherapy and immune systems are achieved, which improves the anti-tumor effect and reduces toxic side effects.

CN116196436BActive Publication Date: 2024-11-26DALIAN UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211567776.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-07
Publication Date
2024-11-26
Estimated Expiration
2042-12-07

AI Technical Summary

Technical Problem

Traditional chemotherapy drugs are difficult to effectively deliver to the tumor site, resulting in poor treatment effects and toxic side effects. The reversal of the tumor immune microenvironment is difficult to achieve, leading to immune escape problems.

Method used

Develop a JQ1 prodrug nanoparticle, covalently linking the reduced sensitive JQ1 prodrug polymer through polyethylene glycol-polylysine (PEG-PLys) as the backbone, enriching it in the tumor using the EPR effect, and Release JQ1 in a high reduction environment, inhibit the expression of BRD4i protein and PD-L1, and realize synergistic treatment of chemotherapy and immune.

Benefits of technology

Through nanoparticles effectively accumulate and release JQ1 at the tumor, the efficacy of chemotherapy drugs is enhanced, toxic and side effects are reduced, tumor immune microenvironment is reversed, and anti-tumor effect is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003986835370000031
    Figure BDA0003986835370000031
  • Figure BDA0003986835370000041
    Figure BDA0003986835370000041
  • Figure BDA0003986835370000051
    Figure BDA0003986835370000051
Patent Text Reader

Abstract

The present invention discloses a JQ1 prodrug nanoparticle that can synergize chemotherapy to reverse the tumor microenvironment, and a preparation method and application thereof. The preparation method comprises the following steps: (1) synthesis of PEG-PLys; (2) synthesis of JQ1 prodrug small molecules; (3) synthesis of PEG-PLys (ss-JQ1) prodrug polymers; (4) synthesis of prodrug nano-micelles. The present invention can form stable prodrug nanoparticles through hydrophilic and hydrophobic interactions, which are enriched in the tumor through blood circulation, and after being internalized by cancer cells, the disulfide bonds are broken in a reducing environment to release JQ1, further compensating for the disadvantage of premature leakage of nano-drugs, and having great advantages in reducing toxic and side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of biomaterials and biomedicine, and in particular to a JQ1 prodrug nanoparticle capable of cooperating with chemotherapy to reverse a tumor microenvironment, and a preparation method and application thereof. Background Art

[0002] Traditional cancer treatment drugs are difficult to achieve the expected therapeutic effect due to their poor solubility and broad spectrum. Moreover, in the actual treatment process, they will also produce great toxic side effects. It is impossible to reach an effective drug concentration per unit time at the tumor site, which will lead to drug resistance, metastasis and recurrence of cancer cells, causing more pain to patients. Therefore, how to effectively deliver chemotherapy drugs to the tumor site has become a hot topic of concern. Studies have found that due to the rapid proliferation of tumor cells, solid tumors have the characteristics of rich blood vessels, poor structural integrity, and lack of lymphatic return, which can retain nano-scale macromolecules and particulate matter. With the introduction of the EPR effect in 1986, nano drug delivery carriers have been designed and applied by more and more people. Based on the EPR effect, scientists have designed a drug transport system: using carrier biomaterials to encapsulate chemotherapy drugs, achieving controlled release of drugs, targeted and fixed-point drug delivery, and overcoming many problems existing in naked drug delivery. Common organic carrier biomaterial nano drug delivery carriers are being designed and applied by more and more people. Nanocarriers deliver drugs to tumor cells through five stages: blood circulation, accumulation in tumor tissue, penetration into the tumor, internalization of tumor cells, and intracellular drug release. Compared with traditional chemotherapy drugs, nanomedicines have many advantages, such as improving drug solubility, prolonging blood circulation, improving bioavailability, reducing side effects, and improving the quality of life of patients.

[0003] At present, dozens of nano-preparations have entered the clinic, such as doxorubicin liposomes, and many have entered the clinical trial stage. However, traditional nano-drugs are difficult to achieve good therapeutic effects because they do not have an active release mechanism; for example, the doxorubicin liposomes approved by the FDA in 1995 have a blood circulation time of up to 30 hours and can be enriched in tumors; but the actual therapeutic effect is not much different from that of free doxorubicin. Further research and analysis show that a large number of liposomes overflow into the blood vessels around the tumor and cannot penetrate into the tumor. In addition, there is a lack of active and rapid release mechanism, which seriously affects the therapeutic effect of the tumor. Nano-prodrugs are an advanced version of nano-drugs. It is modified with anticancer drugs through sensitive groups to prepare low-activity or inactive drugs, and then assembled into nano-prodrugs, which can release the activity of drugs under specific stimulation. The emergence of prodrugs further compensates for the shortcomings of premature leakage of nano-drugs and has great advantages in reducing toxic side effects.

[0004] Immunotherapy has played an increasingly important role in tumor treatment. Tumor immunotherapy is a treatment method that controls and eliminates tumors by changing the tumor immune microenvironment and restoring the body's normal anti-tumor immune response. In recent years, tumor immunotherapy has developed rapidly, and immune checkpoint blockade therapy has produced significant therapeutic effects in a variety of tumors, making immunotherapy expected to become another classic anti-tumor therapy after surgery, radiotherapy, and chemotherapy. Among them, immune checkpoints are inhibitory pathways in the immune system, which are regulated by ligand / receptor interactions. It plays an important role in maintaining autoimmune tolerance and regulating the duration and amplitude of physiological immune responses, thereby preventing the immune system from causing damage and destruction to normal tissues. However, cunning tumor cells also express immune checkpoint molecules to escape the attack of immune cells. Immune checkpoint blockade therapy has produced significant therapeutic effects in a variety of tumors, making immunotherapy expected to become another classic anti-tumor therapy after surgery, radiotherapy, and chemotherapy. The immune checkpoint PD-L1 is highly expressed in tumor cells, and PD-L1 binds to PD-1 on lymphotoxic cells to mediate the co-inhibitory signal of T cell activation, inhibit the killing function of T cells, and play a negative regulatory role in the human immune response. Studies have found that some chemotherapy drugs will also upregulate the expression of PD-L1 in tumor cells during the treatment of cancer. Therefore, blocking the immune checkpoint PD-L1 during the use of chemotherapy drugs to treat tumors is expected to enhance the anti-tumor effect and achieve synergistic chemotherapy and immunotherapy. JQ1 is a small molecule inhibitor known to target epigenetic regulators. It acts on BRD4i protein and can inhibit the expression of PD-L1 in tumor cells. As a small molecule drug, JQ1 is very small and easily interacts with other parts, resulting in unexpected side effects. In order to achieve the accumulation of effective drug concentrations and controllable release of the PD-L1 inhibitor JQ1 in tumor tissues, it is considered to prepare JQ1 nano-prodrugs for synergistic chemotherapy and immunotherapy. Summary of the invention

[0005] To solve the problems of the prior art, the present invention provides a JQ1 prodrug nanoparticle that can synergize chemotherapy to reverse the tumor microenvironment, and a preparation method and application thereof. First, the JQ1 molecule is a PD-L1 inhibitor that can effectively reverse the tumor immune microenvironment. Secondly, a nano prodrug particle with good biocompatibility and strong stability that can actively release drugs in response to endogenous stimuli is constructed. The present invention aims to solve problems such as the nonspecific release of nanodrugs, provide an effective solution to improve the delivery efficiency of nanodrugs and the immune escape problem in the process of tumor treatment, and lay the foundation for subsequent immunochemotherapy synergistic treatment.

[0006] The purpose of the present invention is achieved through the following technical solutions:

[0007] A method for preparing JQ1 prodrug nanoparticles that can synergize chemotherapy to reverse the tumor microenvironment comprises the following steps:

[0008] (1) Synthesis of polyethylene glycol-polylysine (PEG-PLys)

[0009] ① Drop the Lys(TFA)-NCA (trifluoroacetyl lysine cyclic anhydride) solution into the mPEG-NH2 (amino-polyethylene glycol) solution, mix well, and stir in an oil bath at 20-30°C for more than 24 hours; after the reaction, precipitate with ether, rinse repeatedly, and dry to obtain PEG-PLys(TFA);

[0010] The mPEG-NH2 solution is prepared by dissolving mPEG-NH2 in dichloromethane (DCM), removing water to obtain mPEG-NH2 from which water has been removed, and then dissolving the mPEG-NH2 from which water has been removed in anhydrous (N,N-dimethylformamide) DMF to obtain an mPEG-NH2 solution; the Lys(TFA)-NCA solution is prepared by dissolving Lys(TFA)-NCA in anhydrous DMF to obtain a Lys(TFA)-NCA solution;

[0011] The molar ratio of the mPEG-NH2 to Lys(TFA)-NCA is 1:20-30, preferably 1:28; the molar concentration of the Lys(TFA)-NCA solution is 0.15-3M, preferably 0.25M; the molar concentration of the mPEG-NH2 solution is 5-10mM, preferably 8.3mM; the volume ratio of the Lys(TFA)-NCA solution to the mPEG-NH2 solution is 1-2.5:1-2.5, preferably 1:1.

[0012] Based on the above technical solution, preferably, the method for removing moisture is to add a small amount of benzene and mix thoroughly.

[0013] Based on the above technical solution, preferably, the molecular weight of PEG in the mPEG-NH2 is 5-10 kDa.

[0014] ② Dissolve PEG-PLys (TFA) in anhydrous methanol, add NaOH, and stir the reaction overnight in an oil bath at 20-30°C. After the reaction is completed, dialyze the methanol solution containing PEG-PLys and then dry to obtain polyethylene glycol-polylysine (PEG-PLys).

[0015] The molar concentration of the PEG-PLys (TFA) in anhydrous methanol is 2-5 mM, preferably 3 mM; the concentration of NaOH in anhydrous methanol is 0.5-1.5 M, preferably 1 M.

[0016]

[0017] Based on the above technical solution, preferably, the dialysis is first performed by HCl dialysis and then by pure water dialysis.

[0018] Based on the above technical solution, preferably, the molecular weight cut-off (MWCO) of the dialysis bag used for dialysis is 8-14 kDa.

[0019] Based on the above technical solution, preferably, the dialysis fluid is replaced every 8-10 hours.

[0020] (2) Synthesis of JQ1 prodrug small molecule

[0021] ① At 20-30°C, JQ1 was reacted in anhydrous DCM containing TFA (trifluoroacetic acid) for 2-6 h and purified by silica gel chromatography to obtain JQ1-COOH.

[0022] The molar concentration of JQ1 in anhydrous DCM containing TFA (trifluoroacetic acid) is 0.05-0.2 M, preferably 0.1 M; the concentration of TFA in anhydrous DCM containing TFA (trifluoroacetic acid) is 30-50% (v / v).

[0023] ② Dissolve JQ1-COOH in anhydrous DCM, add DMAP (4-dimethylaminopyridine), EDCI (carbodiimide hydrochloride), and DIEA (N,N-diisopropylethylamine), activate the carboxyl group at 0-5°C for 2-4h, then add a THF solution of 2-hydroxyethyl disulfide, stir the reaction at 20-30°C for 20-25h, and purify by silica gel chromatography to obtain JQ1-ss-OH.

[0024] The molar concentration of the JQ1-COOH in anhydrous DCM is 0.05-0.3M, preferably 0.1M; the molar ratio of the JQ1-COOH:DMAP:EDCI:DIEA is 1:2:2:2-1:4:4:4, preferably 1:3:3:3; the molar ratio of the 2-hydroxyethyl disulfide to JQ1-COOH is 5-15:1, preferably 10:1; the concentration of the THF solution of the 2-hydroxyethyl disulfide is 0.5-1.5M, preferably 1M.

[0025]

[0026] (3) Synthesis of PEG-PLys(ss-JQ1) prodrug polymer

[0027] ① Dissolve JQ1-ss-OH in anhydrous DCM, add BTC (triphosgene) solution to the reaction system, react at 0-5°C for 20-30 minutes, then add DMAP solution, react at 0-5°C for 1-3 hours, then transfer to -20-30°C and continue to react for 1-3 hours to obtain a solution of JQ1-ss-OH after the activated hydroxyl reaction. The preparation method of BTC solution is: first dissolve BTC in anhydrous DCM to obtain BTC solution.

[0028] The molar concentration of the JQ1-ss-OH in anhydrous DCM is 20-40 mM, preferably 30 mM; the molar concentration of the BTC solution is 20.4-71.3 mM, preferably 55 mM; the molar ratio of the JQ1-ss-OH to BTC is 1-3.5:1, preferably 2.7:1; the molar concentration of the DMAP solution is 0.17-0.3 M, preferably 0.19 M; the molar ratio of the JQ1-ss-OH to DMAP is 1:3-5, preferably 1:3-4, and more preferably 1:3.2.

[0029] ② Dissolve polyethylene glycol-polylysine (PEG-PLys) in a mixed solvent of anhydrous DCM and DMF, then add DMAP solution, add JQ1-ss-OH solution after the activated hydroxyl reaction, and react for 45-50 hours at 25-30°C in the dark; after the reaction, precipitate with ether, and repeatedly rinse, dialyze, and dry to obtain PEG-PLys (ss-JQ1) prodrug polymer.

[0030] The molar concentration of the polyethylene glycol-polylysine (PEG-PLys) in the mixed solvent of anhydrous DCM and DMF is 0.4-0.8mM, preferably 0.67mM; the volume ratio of anhydrous DCM to DMF in the mixed solvent of anhydrous DCM and DMF is 1:2-5, preferably 1:3; the molar concentration of the DMAP solution is 0.1-0.25M, preferably 0.15M; the molar ratio of the amino group of the polyethylene glycol-polylysine (PEG-PLys) to DMAP is 1:15-30, preferably 1:23; the molar ratio of the hydroxyl group in the JQ1-ss-OH solution after the reaction of the amino group of the polyethylene glycol-polylysine (PEG-PLys) with the activated hydroxyl group is 30-10:1, preferably 15:1.

[0031]

[0032] Where x+y=n.

[0033] Based on the above technical solution, preferably, the dialysis is dialysis with pure water.

[0034] Based on the above technical solution, preferably, the molecular weight cutoff (MWCO) of the dialysis bag used for dialysis is 8-14 kDa.

[0035] Based on the above technical solution, preferably, the dialysis fluid is replaced every 8-10 hours.

[0036] (4) Synthesis of prodrug nanomicelles

[0037] The amphiphilic prodrug polymer molecule, the prodrug polymer is composed of two parts, hydrophilic PEG and hydrophobic drug JQ1. The hydrophilic and hydrophobic interactions between molecules are used to assemble PEG-PLys (ss-JQ1) into nanomicelles in a buffer solution (PBS). The nanomicelles are obtained by a nanoparticle precipitation method. The PEG-PLys (ss-JQ1) prodrug polymer is dissolved in DMSO to obtain a sample solution, and then the sample solution is dripped into a low-temperature PBS solution. During the sample dripping process, 0-10°C and high-speed (500-800rmp) stirring are maintained. After the sample is completely dripped into PBS, it is allowed to stand for 20-30 minutes and dialyzed to obtain a nanomicelle stock solution; the nanomicelle sample stock solution is ultrafiltered and concentrated using an ultrafiltration tube (MWCO: 3-10kDa) to obtain a nanoparticle solution NP (ss-JQ1) (final concentration: 5-10mg / mL).

[0038] The concentration of the PEG-PLys (ss-JQ1) prodrug polymer in the sample solution is 5-10 mg / mL, preferably 8 mg / mL; the concentration of the PBS solution is 10 mM, and the pH is 7.4; the volume ratio of the sample solution to the PBS solution is 1:5-20, preferably 1:10.

[0039] Based on the above technical solution, preferably, the sample solution is dripped dropwise into the low-temperature PBS solution.

[0040] Based on the above technical solution, preferably, the dialysis is performed using pure water, the molecular weight cutoff (MWCO) of the dialysis bag used for dialysis is 3-10 kDa, and the pure water is replaced every 2-3 hours during dialysis. The dialysis is repeated 4-5 times.

[0041] Based on the above technical solution, preferably, the molecular weight cut-off (MWCO) of the ultrafiltration tube is 3-10 kDa.

[0042] The present invention also relates to protecting JQ1 prodrug nanoparticles prepared by the above method and capable of cooperating with chemotherapy to reverse the tumor microenvironment.

[0043] The present invention also relates to the use of the JQ1 prodrug nanoparticles in the treatment of tumors (such as breast cancer, lung cancer, liver cancer, and bile duct cancer).

[0044] After being prepared into nanoparticles, the present invention can effectively accumulate in tumor tissues through the EPR effect, and the presence of disulfide bonds as reduction-responsive sensitive bonds can consume a large amount of GSH in tumor cells, further improving the effect of chemotherapy and immunotherapy combined treatment. Beneficial effects of the present invention:

[0045] The present invention can form stable prodrug nanoparticles through hydrophilic and hydrophobic interactions, which are enriched in tumors through blood circulation. After being internalized by cancer cells, the disulfide bonds are broken in a reducing environment to release JQ1, further compensating for the disadvantage of premature leakage of nanomedicines, and having great advantages in reducing toxic side effects.

[0046] As a small molecule inhibitor, JQ1 can act on the BRD4i protein in cancer cells, further inhibiting the upregulation of the immune blockade point PD-L1, thereby changing the tumor immune microenvironment. The development of JQ1 prodrug nanoparticles provides a further basis for the subsequent immunotherapy and chemotherapy synergistic treatment of cancer. Chemotherapy and immunotherapy synergistic treatment further enhance the efficacy of chemotherapy drugs and achieve a more excellent anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 is the NMR result of PEG-PLys;

[0048] Figure 2 This is the JQ1-COOH NMR result;

[0049] Figure 3 The results of JQ1-ss-OH NMR

[0050] Figure 4 is the mass spectrometry result of JQ1-ss-OH;

[0051] Figure 5 This is the NMR result of PEG-PLys-(ss-JQ1);

[0052] Figure 6 To characterize the particle size of nanoparticles;

[0053] Figure 7 is the drug release curve of nanoparticle JQ1;

[0054] Figure 8 for the cytotoxicity of nanoparticles;

[0055] Fig. 9 Laser confocal imaging of nanoparticles after incubation with 4T1 for 2 and 6 hours;

[0056] Fig.10 The cytotoxicity of nanoparticles and the chemotherapy drug camptothecin. DETAILED DESCRIPTION

[0057] The following non-limiting embodiments may enable a person skilled in the art to more fully understand the present invention, but are not intended to limit the present invention in any way.

[0058] With polyethylene glycol-polylysine (PEG-PLys) as the main chain, the prodrug polymer molecule PEG-PLys (ss-JQ1) containing a reduction-sensitive disulfide bond of JQ1 is covalently linked to the lysine side chain. The tumor microenvironment is a highly reducing environment, and the disulfide bonds of the prodrug polymer are reduced to release active JQ1. JQ1 acts on the BRD4i protein and can inhibit the expression of PD-L1 in tumor cells.

[0059] Example 1

[0060] (1) Synthesis of PEG-PLys

[0061]

[0062] First, mPEG10k-NH2 was dehydrated. 500mg mPEG(10k)-NH2 (0.05mmol) was weighed into a 25mL reaction bottle, 2mL DCM was added to completely dissolve mPEG-NH2, and 10mL benzene was added to mix well. The reaction bottle was placed in liquid nitrogen and the solution was evenly frozen on the bottle wall. The solution was then vacuumed to remove moisture. After dehydration, the mPEG-NH2 was transferred to a glove box under anhydrous and oxygen-free conditions for the next reaction. Lys(TFA)-NCA was polymerized onto the main chain of PEG through a ring-opening polymerization reaction initiated by mPEG-NH2. mPEF-NH2 was dissolved in 3 mL of anhydrous DMF. 402 mg (1.5 mmol) of Lys(TFA)-NCA was weighed into a centrifuge tube, and 3 mL of anhydrous DMF was added to completely dissolve Lys(TFA)-NCA. Lys(TFA)-NCA was then dropped into the reaction flask and mixed thoroughly. The reaction flask was placed in an oil bath at 30°C and stirred for 25-30 hours. After the reaction was completed, the reaction product was preliminarily purified by ether precipitation. Cold ether was used for repeated precipitation for 3 times to fully remove the reaction monomers. The reaction product was then vacuum-dried with a cold trap to obtain white solid PEG-PLys(TFA) (820 mg, reaction yield 90.9%). The product was stored at 4°C for use.

[0063] The amino protecting group TFA on the side chain of PEG-PLys (TFA) needs to be removed by hydrolysis in a methanol solution containing NaOH (15 mL, 1 M). The product PEG-PLys (TFA) (600 mg) obtained in the previous step was placed in a 50 mL reaction bottle, 15 mL of anhydrous methanol solution was added until completely dissolved, 0.6 g of NaOH particles were weighed, 1. mL of NaOH particles were added to completely dissolve the NaOH particles, and then added to the reaction bottle, and stirred for 24 hours under 25 ° C oil bath conditions. After the reaction, the methanol solution containing PEG-PLys was transferred to a dialysis bag (MWCO: 10 kDa) for dialysis. The first two times were dialyzed with 1M HCl, and the latter two times were dialyzed with ultrapure water. The dialysate was replaced every 10 hours. After the dialysis was completed, the sample was vacuum dried using a freeze dryer to obtain 530 mg of white powder (reaction yield 88.3%), and the product was stored at 4 ° C for use.

[0064] (2) Synthesis of JQ1 prodrug small molecule

[0065]

[0066] First, the synthesis of JQ1-COOH, weigh 456mg JQ1 (1mmol) in a 50mL reaction bottle, add 10mL of anhydrous DCM containing 40% (v / v) TFA to dissolve the JQ1 solid, and stir the reaction at room temperature for 4h. The reaction solution was concentrated by rotary evaporation, and JQ1-COOH was obtained after silica gel chromatography (DCM) as a yellow powder 430mg (yield 94.3%). The synthesis of JQ1-ss-OH needs to be operated in a glove box. Weigh 200mg (0.5mmol) of JQ1-COOH and place it in a 50mL reaction bottle, add 5mL of anhydrous DCM to dissolve JQ1-COOH, add DMAP 183mg (1.5mmol), EDCI 288mg (1.5mmol), DIEA 194mg (0.25mL1.5mmol), and activate the carboxyl group at 0℃ for 2-4h. 766 mg (10 mmol) of 2-hydroxyethyl disulfide was dissolved in 10 mL of anhydrous THF and quickly added to the mixture reaction system and stirred at room temperature for 24 h. JQ1-ss-OH was purified by silica gel chromatography (DCM) to obtain 315 mg of light yellow powder (yield 69.1%).

[0067] (3) Synthesis of PEG-PLys(ss-JQ1) prodrug polymer

[0068]

[0069] The synthesis of JQ1 prodrug polymer needs to be performed in a glove box. First, activate the active hydroxyl group of the prodrug small molecule, weigh 160 mg of JQ1-ss-OH (0.3 mmol) and place it in a 100 mL reaction bottle, first dissolve the prodrug small molecule JQ1-ss-OH with 10 mL of anhydrous DCM, weigh 33 mg of BTC (0.11 mmol) and dissolve it with 2 mL of anhydrous DCM, add the BTC solution to the reaction system, and react for 30 minutes under ice bath conditions; weigh 117.3 mg of DMAP (0.96 mmol) and dissolve it with 5 mL of anhydrous DCM, slowly drip it into the reaction system, react for 1 hour under ice bath conditions, and then transfer to room temperature conditions to continue the reaction for 1 hour. At the same time, 266 mg PEG-PLys (0.02 mmol) was weighed and placed in a 250 mL reaction bottle and dissolved with 15 mL of anhydrous DCM and 15 mL of DMF. 56 mg of DMAP (0.46 mmol) was weighed and dissolved with 3 mL of anhydrous DCM and added to the reaction system of PEG-PLys. The solution of JQ1-ss-OH after the activation of the hydroxyl group was slowly dripped into the reaction system of PEG-PLys and reacted for 48 h at room temperature in the dark. After the reaction was completed, ice ether was used for precipitation. After repeated precipitation for 3 times, the ether supernatant had no obvious fluorescence. The ether was drained using a cold trap to obtain a crude white solid. A small amount of DMSO was used to dissolve the white solid, and pure water was used for 4 times of dialysis, and the water was changed every 8 hours. The dialyzed sample was dried using a freeze dryer, and light was required during the process to finally obtain 360 mg of a white solid product.

[0070] (4) Synthesis of prodrug nanomicelles

[0071] Amphiphilic prodrug polymer molecules, the prodrug polymer consists of two parts: hydrophilic PEG and hydrophobic drug JQ1. PEG-PLys (ss-JQ1) is assembled into nanomicelles in a buffer solution (PBS) by utilizing the hydrophilic and hydrophobic interactions between molecules. Nanomicelles are obtained by nanoparticle precipitation method. PEG-PLys (ss-JQ1) is dissolved in DMSO, and the concentration of the sample is 8 mg / mL. The prepared sample (8 mL) is slowly dripped into 40 mL of low-temperature (4°C) PBS (10mM, pH 7.4). During the process of dripping the sample, keep the low temperature (4°C) and high-speed (700rmp) stirring. After the sample is completely dripped into PBS, it is placed for 30 minutes and transferred to a dialysis bag (MWCO: 3kDa) for pure water dialysis. The pure water is replaced every 3 hours, and the nanomicelle stock solution is obtained by repeating 4 times. The nanomicelle sample stock solution was ultrafiltered and concentrated using an ultrafiltration tube (MWCO: 3 kDa) to obtain a nanoparticle solution NP (ss-JQ1) (final concentration: 7.5 mg / mL).

[0072] Example 2

[0073] The structural correctness, physicochemical properties, cellular uptake, cytotoxicity and other capabilities of the prodrug polymer and nanoparticles prepared in Example 1 were analyzed. The results are as follows:

[0074] (1) PEG-PLys NMR results

[0075] pass 1 H NMR confirmed the structural correctness of mPEG-PLys. Figure 1 As shown, D2O is used as the deuterated solvent. 1 In the H NMR spectrum, the chemical shift of the methylene proton peak on the mPEG main chain is δ3.90-3.45ppm, the chemical shift of the methylene proton peak at the β-δ position of the lysine side chain is δ1.90-1.30ppm, the chemical shift of the proton peak on the α-quaternary carbon of lysine is δ4.30ppm, the chemical shift of the methylene proton peak at the ω position of the lysine side chain is δ3.00ppm, and the chemical shift of the methoxy proton peak at the terminal of mPEG is δ3.37ppm. The structural correctness of mPEG-PLys can be proved based on the coupling coefficient of each proton peak in the spectrum and the splitting of the peak, and the degree of polymerization of lysine can be calculated to be 23.0 based on the proton peak area.

[0076] (2) JQ1-ss-OH NMR and mass spectrometry results

[0077] ①JQ1-COOH passes 1 H NMR confirmed the correctness of JQ1-COOH, and the results were tested in deuterated DMSO as solvent. Figure 2 The proton peaks of the three methyl groups in the JQ1 molecule at a chemical shift of δ1.42ppm disappeared, and the proton peak of the carboxyl group in JQ1-COOH appeared at a chemical shift of δ12.51ppm, proving that JQ1-COOH successfully removed the Boc group and had a correct structure.

[0078] ②JQ1-ss-OH Figure 3 shown 1 H NMR results showed that with deuterated DMSO as solvent, the proton peak of the carboxyl group in JQ1-COOH disappeared at a chemical shift of δ12.51ppm, and the proton peak of the methylene group in 2-hydroxyethyl disulfide appeared at a chemical shift of δ2.75-3.96ppm, proving that JQ1-ss-OH was successfully synthesized. Figure 4 Mass spectrum results: JQ1-ss-OH [M] +: 536.07, [M+H] +: m / z = 537.08.

[0079] (3) H NMR spectrum results of PEG-PLys-(ss-JQ1)

[0080] PEG-PLys(ss-JQ1)1 H NMR results are as follows Figure 5 As shown. Deuterated DMSO was used as solvent. 1 The chemical shift in the H NMR spectrum was δ7.50-7.80ppm and a new proton peak appeared. Compared with the peak position of the 1H NMR spectrum of JQ1-ss-OH, it was consistent and attributed to the aromatic proton peak of JQ1, proving that JQ1 was successfully grafted onto the side chain of lysine. According to the area ratio of the proton peak in the 1H NMR spectrum, 8.0 JQ1 molecules were grafted onto each PEG molecule. The results prove the successful synthesis of PEG-PLys (ss-JQ1) molecules.

[0081] (4) Characterization of nanoparticle size

[0082] like Figure 6 As shown, the average particle size of the nanoparticles measured by a nanoparticle size analyzer is 106 nm and PDI is 0.214.

[0083] (5) JQ1 release curve of nanoparticles

[0084] The drug release of JQ1 was simulated in vitro under different pH and glutathione (GSH) environments. Figure 7 The curve results show that in the presence of 10 mM GSH, the release of JQ1 reaches 75% in about 5 hours and 95% in 10 hours. However, there is almost no JQ1 release in the presence of 0 mM GSH. Low pH has almost no effect on the release of JQ1.

[0085] (6) Cytotoxicity of Nanoparticles (MTT Method)

[0086] The collected 4T1 cell suspension was diluted with 1640 medium (containing 10% serum and 1% double antibody) to a cell concentration of 1×10 5 / mL, and then evenly inoculated into a 96-well plate, 100 μL was added to each well, and cultured in a cell culture incubator (37°C, 5% CO2) for 24 hours. The old culture medium was discarded, and 100 μL of culture medium containing samples of different concentrations (NP (ss-JQ1) was configured as JQ1 with drug concentrations of 0 μM, 0.4 μM, 0.8 μM, 1.6 μM, 3.2 μM, 6.3 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM) was added to continue culturing in a cell culture incubator for 48 hours, the culture medium was discarded, and the cells were washed twice with PBS. 100 μL of culture medium containing MTT (MTT concentration was 0.5 mg / mL) was added to each well, and the cells were continued to be cultured in an incubator for 4 hours, the supernatant was discarded, and 100 μL of DMSO was added to each well to dissolve the blue-purple crystalline formazan produced in the living cells. After mixing in the dark, the absorbance at 570 nm was measured by an enzyme marker (minus the background absorbance at 630 nm), and the average cell survival rate of each group was calculated according to the cell survival rate formula. The culture medium group was the blank control group, and the group with cells but no drug treatment was the positive control group.

[0087] Cell survival rate = (absorbance value of the test group - absorbance value of the blank control group) / (absorbance value of the positive control group - absorbance value of the blank control group) × 100%

[0088] The toxicity of nanoparticles to 4T1 cells was studied using the MTT method. Figure 8 As shown, the IC50 is 5.37 μM.

[0089] (7) Cell uptake experiment

[0090] Hoechst dye was used to stain the cell nucleus, AF647 was used to label the nanoparticles, and 4T1 cells were used for CLSM laser confocal microscopy to observe the uptake of nanoparticles by 4T1 cells over a certain period of time (2h, 8h). 4 2 mL of fresh 1640 medium (containing 10% serum and 1% double antibody) containing AF647-labeled nanoparticles was added to a 35-mm dish with 100 μg / mL of 1 ... Fig. 9 As shown in the figure, the experimental results show that only a small number of nanoparticles enter the cells after 2 hours of co-incubation with 4T1 cells, and some nanoparticles are distributed on the surface of the cell membrane. After 6 hours of co-incubation with 4T1 cells, most of the nanoparticles are observed to enter the cells.

[0091] (8) Cytotoxicity of nanoparticles and the chemotherapeutic drug camptothecin (CPT)

[0092] The collected 4T1 cell suspension was diluted with 1640 medium (containing 10% serum and 1% double antibody) to a cell concentration of 1×10 5 / mL, and then evenly inoculated into a 96-well plate, 100μL was added to each well, and cultured in a cell culture incubator (37°C, 5% CO2) for 24 hours. The old culture medium was discarded, and 100μL of samples containing different concentrations (NP (ss-JQ1) and chemotherapy drug CPT were configured as JQ1 and CPT were 0μM (the concentrations of JQ1 and CPT were both 0μM), 0.4μM (the concentrations of JQ1 and CPT were both 0.4μM), 0.8μM (the concentrations of JQ1 and CPT were both 0.8μM), 1.6μM (the concentrations of JQ1 and CPT were both 1.6μM), 3.2μM (the concentrations of JQ1 and CPT were both 3.2μM), 6.3μM (the concentrations of JQ1 and CPT were both 6.3μM) were added. ), 12.5μM (the concentrations of JQ1 and CPT were both 12.5μM), 25μM (the concentrations of JQ1 and CPT were both 25μM), 50μM (the concentrations of JQ1 and CPT were both 50μM), 100μM (the concentrations of JQ1 and CPT were both 100μM)) culture medium was continued to be cultured in a cell culture incubator for 48 hours, the culture medium was discarded, and the cells were washed twice with PBS. 100μL of culture medium containing MTT (MTT concentration was 0.5mg / mL) was added to each well, and the cells were continued to be cultured in an incubator for 4 hours. The supernatant was discarded, and 100μL of DMSO was added to each well to dissolve the blue-purple crystalline formazan produced in the living cells. After shaking and mixing in the dark, the absorbance value at 570nm was measured by an enzyme marker (minus the background absorbance value at 630nm), and the average cell survival rate of each group was calculated according to the cell survival rate formula. The culture medium group was the blank control group, and the group with cells but no drug treatment was the positive control group.

[0093] Cell survival rate = (absorbance value of the test group - absorbance value of the blank control group) / (absorbance value of the positive control group - absorbance value of the blank control group) × 100%

[0094] The MTT method was used to study the toxicity of nanoparticles and the chemotherapy drug camptothecin on 4T1 cells. Fig.10 As shown in the figure, the nanoparticles and the chemotherapy drug camptothecin CPT acted together on 4T1 cells, and the results showed a stronger ability to inhibit cell proliferation, so the immunochemotherapy synergistic treatment method is more effective.

[0095] After the nanoparticles of the present invention are prepared, they are injected into the tail vein. Under the action of the EPR effect, the nanoparticles will be accumulated in large quantities at the tumor site. After being taken up by tumor cells, they will play a role and reverse the tumor immunosuppressive microenvironment. They can be delivered together with chemotherapy drugs to achieve chemotherapeutic and immunotherapy synergistic treatment, further improving the anti-tumor effect.

Claims

1. A method for preparing JQ1 prodrug nanoparticles that can synergize chemotherapy to reverse the tumor microenvironment, characterized in that: The steps include: (1) Synthesis of PEG-PLys ① Drop the Lys(TFA)-NCA solution into the mPEG-NH2 solution, mix well, and stir in an oil bath at 20-30°C for more than 24 hours; after the reaction, precipitate with ether, rinse repeatedly, and dry to obtain PEG-PLys(TFA); ② Dissolve PEG-PLys (TFA) in anhydrous methanol, add NaOH, and stir the reaction overnight in an oil bath at 20-30°C; after the reaction, dialyze the methanol solution containing PEG-PLys, and then dry it to obtain PEG-PLys; (2) Synthesis of JQ1 prodrug small molecule ① At 20-30°C, JQ1 was reacted in anhydrous DCM containing TFA for 2-6h to obtain JQ1-COOH; ② Dissolve JQ1-COOH in anhydrous DCM, add DMAP, EDCI, and DIEA, activate the carboxyl group at 0-5°C for 2-4h, then add a THF solution of 2-hydroxyethyl disulfide, and stir the reaction at 20-30°C for 20-25h to obtain JQ1-ss-OH; (3) Synthesis of PEG-PLys(ss-JQ1) prodrug polymer ① Dissolve JQ1-ss-OH in anhydrous DCM, add BTC solution to the reaction system, react at 0-5°C for 20-30 minutes, then add DMAP solution, react at 0-5°C for 1-3 hours, then transfer to 20-30°C and continue to react for 1-3 hours to obtain a solution of JQ1-ss-OH after the hydroxyl group is activated; ② Dissolve PEG-PLys in a mixed solvent of anhydrous DCM and DMF, add DMAP solution, add JQ1-ss-OH solution after the hydroxyl activation reaction, and react for 45-50 hours at 25-30°C in the dark; after the reaction, precipitate with ether, rinse repeatedly, dry and dialyze, and obtain PEG-PLys (ss-JQ1) prodrug polymer after drying; Where x+y=n; (4) Synthesis of prodrug nanomicelles The PEG-PLys (ss-JQ1) prodrug polymer is dissolved in DMSO to obtain a sample solution, and then the sample solution is dripped into a PBS solution. During the dripping process, the stirring is maintained at 0-10°C and 500-800 rpm. After the sample is completely dripped, it is allowed to stand for 20-30 minutes and dialyzed to obtain a nanomicelle stock solution. The nanomicelle sample stock solution is then ultrafiltered and concentrated using an ultrafiltration tube to obtain a nanoparticle solution NP (ss-JQ1); The molecular weight of PEG in the mPEG-NH2 is 5-10 kDa; In step (1), the molar ratio of mPEG-NH2 to Lys(TFA)-NCA is 1:20-30; In step (2), the molar concentration of JQ1 in anhydrous DCM containing TFA is 0.05-0.2 M; the concentration of TFA in anhydrous DCM containing TFA is 30-50%, v / v; The molar concentration of the JQ1-COOH in anhydrous DCM is 0.05-0.3M; the molar ratio of the JQ1-COOH, DMAP, EDCI and DIEA is 1:2:2:2-1:4:4:4; the molar ratio of the 2-hydroxyethyl disulfide to JQ1-COOH is 5-15:1; the concentration of the THF solution of the 2-hydroxyethyl disulfide is 0.5-1.5M; In step (3), the molar ratio of the hydroxyl groups in the JQ1-ss-OH solution after the reaction of the amino groups of the PEG-PLys with the activated hydroxyl groups is 30-10:

1.

2. The preparation method according to claim 1, characterized in that: In step (1), the mPEG-NH2 solution is prepared by dissolving mPEG-NH2 in DCM, removing water to obtain mPEG-NH2 from which water has been removed, and then dissolving the mPEG-NH2 from which water has been removed in anhydrous DMF to obtain an mPEG-NH2 solution; the Lys(TFA)-NCA solution is prepared by dissolving Lys(TFA)-NCA in anhydrous DMF to obtain a Lys(TFA)-NCA solution.

3. The preparation method according to claim 1 or 2, characterized in that: In step (1), the molar concentration of the Lys(TFA)-NCA solution is 0.15-3M; the molar concentration of the mPEG-NH2 solution is 5-10mM; the volume ratio of the Lys(TFA)-NCA solution to the mPEG-NH2 solution is 1-2.5:1-2.5; The molar concentration of the PEG-PLys (TFA) in anhydrous methanol is 2-5 mM; the concentration of NaOH in anhydrous methanol is 0.5-1.5 M.

4. The preparation method according to claim 1, characterized in that: In step (3), the molar concentration of the JQ1-ss-OH in anhydrous DCM is 20-40 mM; the molar concentration of the BTC solution is 20.4-71.3 mM; the molar ratio of the JQ1-ss-OH to the BTC is 1-3.5:1; the molar concentration of the DMAP solution is 0.17-0.3 M; the molar ratio of the JQ1-ss-OH to the DMAP is 1:3-5; The molar concentration of the PEG-PLys in the mixed solvent of anhydrous DCM and DMF is 0.4-0.8 mM; the volume ratio of anhydrous DCM to DMF in the mixed solvent of anhydrous DCM and DMF is 1:2-5; the molar concentration of the DMAP solution is 0.1-0.25 M; the molar ratio of the amino group of the PEG-PLys to DMAP is 1:15-30.

5. The preparation method according to claim 1, characterized in that: In step (4), the concentration of PEG-PLys (ss-JQ1) prodrug polymer in the sample solution is 5-10 mg / mL; the concentration of PBS solution is 10 mM, and the pH is 7.4; the volume ratio of the sample solution to the PBS solution is 1:5-20.

6. The preparation method according to claim 1, characterized in that: In step (1), the dialysis is first performed with HCl and then with pure water; in step (3), the dialysis is performed with pure water; In steps (1) and (3), the molecular weight cutoff of the dialysis bag used in the dialysis is 8-14 kDa; the dialysis fluid is replaced every 8-10 hours; In step (4), the molecular weight cut-off of the ultrafiltration tube is 3-10 kDa.

7. JQ1 prodrug nanoparticles prepared by the method according to any one of claims 1 to 6 that can synergize chemotherapy to reverse the tumor microenvironment.

8. Use of the JQ1 prodrug nanoparticles according to claim 7 in the preparation of tumor therapeutic drugs, characterized in that: The tumor is breast cancer.